THL-1

N/A

Report date: 2026/03/19 16:57:20

Base Information

Drug NameTHL-1
Drug Alias Nameanti-tumor/CD3/CD28 scTsAb (Beijing ABT Genetic Engineering Technology)anti-CD3/anti-CD28/anti-CEA trispecific T-cell engager (Beijing ABT Genetic Engineering Technology)THL-1
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Trispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionT cell surface glycoprotein CD3 modulatorsT-cell-specific surface glycoprotein CD28 modulatorsCarcinoembryonic antigen related cell adhesion molecule 5 modulators
TargetsT-cell-specific surface glycoprotein CD28Carcinoembryonic antigen related cell adhesion molecule 5T cell surface glycoprotein CD3
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaPending
Originator CompaniesBeijing Applied Biological Technologies Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBeijing Applied Biological Technologies Co Ltd
Active IndicationsN/A
Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A
Related LinksN/A